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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown
to produce long-term symptom improvement in Parkinson’s disease. The aim of this study
was to identify the target symptoms that show the most improvement at 1 year and at 5 years
after STN-DBS.
Methods: This was a 5-year cohort study of 41 consecutive patients treated with bilateral STN-
DBS. Clinical evaluations were performed 1 month prior to surgery and 1 year and 5 years after
surgery. The outcome measurements at 1 year and 5 years were the changes compared with
the baseline in Unified Parkinson’s Disease Rating Scale (UPDRS) parts I, II, III, and IV scores,
the Hoehn and Yahr stage, and Schwab and England Activities of Daily Living (SEADL) scores
in the conditions of off-medication/on-stimulation and off-medication/off-stimulation.
Further analysis included changes in the levodopa equivalent daily dose.
Results: When compared to the preoperative baseline off-medication condition, significant im-
provements were observed in the UPDRS parts I, II, III, and IV and SEADL (p < 0.001) scores in
the off-medication/on-stimulation condition 1 year after STN-DBS. Five years after STN-DBS,
improvements in UPDRS scores were observed only for parts II, III, and IV (p < 0.001). In theave no conflicts of interest relevant to this article.
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836 J.-L. Jiang et al.off-medication/off-stimulation condition, no significant improvement was observed. At 5
years, significant deteriorations were observed in scores for the UPDRS part III axial subitem
(p Z 0.005), UPDRS part I (p Z 0.005), UPDRS part II (p < 0.001), and SEADL (p Z 0.001).
Conclusion: The long-term effect of STN-DBS on motor function is promising, although the
magnitude of its effectiveness varied over the 5-year period.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder. It is characterized by muscle
rigidity, resting tremor, bradykinesia, and postural insta-
bility. The pathologic hallmarks of the disease are the
degeneration of dopaminergic neurons in the substantia
nigra pars compacta of the midbrain and the presence of
Lewy bodies, which are cytoplasmic aggregations of the
protein a-synuclein in brain neurons. Exposure to various
toxins or pesticides may be a secondary etiology. PD is
likely to be a result of multiple factors, including normal
aging, genetic predisposition, and environmental expo-
sure.1,2 Although an optimal pharmacological therapy with
levodopa and other adjuvant regimes can be achieved,
complications associated with the treatment of PD, such as
dyskinesia and motor fluctuation, inevitably occur 5 years
after the initiation of therapy.3,4 The progressive decline in
motor function and the comorbidity associated with PD
negatively affect health-related quality of life.5 Since the
first application of deep brain stimulation of the sub-
thalamic nucleus (STN-DBS) for PD6 in 1993, high frequency
stimulation of the STN has rapidly become the surgical
treatment of choice. The long-term effects of STN-DBS on
medically refractory PD have been well documented. Ac-
cording to some reports, the motor improvement induced
by STN-DBS is sustained for up to 5e8 years after sur-
gery,3,6e13 but part of the initial improvement, mainly
regarding axial signs, become progressively deteriorated.
However, the effects of STN-DBS on the motor and non-
motor symptoms may vary. The aim of this study was to
identify the target symptoms that show the most
improvement at short-term (1 year) and long-term (5 year)
follow-up in the same group of patients after STN-DBS.Figure 1 (A) Preoperative computed tomography and (B)
magnetic resonance imaging were both performed for the
stereotactic surgery and to localize the subthalamic nucleus.
(C) Postoperative computed tomography and (D) magnetic
resonance imaging were conducted to verify the electrode
coordinates and to evaluate any neurological lesions, such as
intracerebral hemorrhage.Methods
Patient enrollment
From 2002 to 2007, 41 patients from a single DBS center in
Taiwan who underwent bilateral STN-DBS were enrolled in
this cohort study. The diagnosis of PD followed the diag-
nostic criteria of the United Kingdom PD Society Brain
Bank.14 The inclusion criteria were: (1) a good levodopa
response on the Unified PD Rating Scale (UPDRS) part III; (2)
drug-related complications (e.g., dyskinesia, oneoff phe-
nomenon, or psychiatric symptoms), even under optimal
antiparkinsonian medication adjustments; (3) no structural
lesions on the brain magnetic resonance imaging (MRI); and
(4) an absence of dementia. The study was approved by theTzu Chi General Hospital Research Ethical Board in Hualien,
Taiwan. All the patients provided written informed consent
for STN-DBS surgery and for the study’s evaluation
procedure.
Surgical procedure
All the patients were evaluated for the STN-DBS surgery by
standard MRI scans (1.5-T; General Electric, Milwaukee, WI,
USA), using T1-weighted axial images (0.75 mm thick) and
T2-weighted axial images (2 mm thick). The quadripolar
DBS electrodes (model 3389; Medtronic, Englewood, CO,
USA) were implanted after the microelectrode recording
and test stimulation procedures. After 1 week, the elec-
trode cables were connected to an implantable pulse
generator (Kinetra; Medtronic, Minneapolis, MN, USA). The
surgical procedures have been described in detail in our
previous study, and the same surgical team performed all
the operations.15 We arranged a postoperative computed
tomography immediately after the operation to ensure that
the correct target was used for the stimulating electrode
for each patient and an MRI 3 months later (Fig. 1).16 We
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contact to identify the electrode contact with the maximal
clinical benefit.
Study design
The study was an open, nonrandomized, prospective cohort
designed to evaluate changes in symptom improvement from
1 year to 5 years after bilateral STN-DBS. The patients were
evaluated in the defined off-medication/on-stimulation and
in the defined off-medication/off-stimulation conditions.
The off-medication condition was evaluated after the with-
drawal of dopaminergic medication for at least 12 hours, as
defined by the Core Assessment Program for Surgical Inter-
ventional Therapy in PD.17 Off-stimulation was defined
either by the DBS being turned off for at least 4 hours or by
the maximal tolerable period, if the DBS was turned off for
less than 4 hours. UPDRS parts I, II, III, and IV scores, the
Hoehn and Yahr (H&Y) stage, and Schwab and England
Activities of Daily Living (SEADL) scores were obtained at
1 year and 5 years after the surgery.
Outcome measure
The outcome measurements were changes compared to the
baseline in UPDRS part III total motor scores (motor skills
were assessed by the range of the scores from 0 to 108 and
by a reduction in the scores that indicated an improvement
in function) as well as subscores for tremor at rest (items 20
and 21), rigidity (item 22), bradykinesia (items 23e26 and
31), posture and gait (items 28 and 29), and axial signs
(items 18 and 27e30) in the two different treatment con-
ditions at 1 year and 5 years. UPDRS part I (assessment of
mentation, behavior, and mood; scores 0e16), part II
(assessment of activities of daily living; scores 0e52), and
part IV (assessment of the severity of the disability related
to dyskinesia; scores 0e23) scores, the H&Y stage and
SEADL scores (measurement of activities of daily living;
0e100%, with 100% indicating normal function and 70% or
lower indicating that patients need the help of a caregiver)
were also assessed. Further analysis included changes in
the levodopa equivalent daily dose (LEDD) at 1 year and 5
years after surgery compared to the preoperative status.
Statistical analysis
The descriptive analysis was used for both the demographic
data and the improvement percentage of the UPDRS and
SEADL scores. Because normality could not be assumed for
the relatively small group of patients, nonparametric
testing was used. The Wilcoxon signed-rank test was used
to compare UPDRS scores, the H&Y stage and SEADL scores.
Repeated measures analysis via the generalized estimating
equation was used to calculate the LEDD. Missing data were
not entered. The data are presented as the
means  standard deviation. A p value < 0.05 was consid-
ered to indicate statistical significance. The Bonferroni
adjustment was also used to control for overall type-I error
from multiple comparisons. The statistical significance
level of 0.016 (Z 0.05/3) was used for the statistical tests
when there were three comparisons for each outcomevariable. All the p values were two tailed. The statistical
analyses were performed using the SPSS statistical package,
version 19 (SPSS Inc., Chicago, IL, USA).
Results
Between 2002 and 2007, 100 PD patients underwent bilat-
eral STN-DBS at Tzu Chi General Hospital in Hualien,
Taiwan. Complete data were obtained from 41 patients at
the 1-year and 5-year follow-ups. Among these patients, 29
were men, and 12 were women. Their mean age at onset
was 46.5  11.9 years, their mean age at surgery was
56.3  11.7 years, and the mean of their disease duration
was 10.2  5.1 years. The mean H&Y stage was 3.1  0.8.
Off-medication/on-stimulation evaluation
Significant improvements were observed in the UPDRS part I
(3.34  1.9 vs. 2.17  1.4; p < 0.001), part II (19.59  8.3
vs. 9.61  5.1; p < 0.001), part III (47.3  14.0 vs.
23.02  9.0; p < 0.001), and part IV (5.07  3.8 vs.
1.07  1.5; p < 0.001) scores at 1 year after STN-DBS when
compared to the preoperative baseline off-medication
condition. Significant improvements were also observed in
the SEADL scores (77.07  2.7 vs. 94.76  7.7; p < 0.001).
Five years after STN-DBS, improvements in the UPDRS
scores were observed only for part II (19.59  8.3 vs.
14.37  7.1; p < 0.001), part III (47.3  14.0 vs. 28.32  10;
p < 0.001), and part IV (5.07  3.8 vs. 1.97  2.2;
p < 0.001) when compared to the preoperative baseline
off-medication condition. No significant improvement was
observed in the SEADL scores (77.07  2.7 vs. 79.74  21.6;
p Z 0.260). However, the effects of STN-DBS had declined
significantly at the 5-year follow-up for all the parts of the
UPDRS, the H&Y stage, and the SEADL (p < 0.001,
p Z 0.001, and p < 0.001, respectively).
Nevertheless, significantly sustained DBS effects were
observed in the UPDRS part III subitems of tremor and ri-
gidity at the 5-year follow-up (Table 1, Fig. 2).
Off-medication/off-stimulation evaluation
At the 1-year follow-up after STN-DBS, no significant
improvement was observed when compared to the preop-
erative baseline off-medication condition.
At the 5-year follow-up, when compared to the preopera-
tive baseline off-medication condition, significant de-
teriorations were observed in the scores for the UPDRS part III
axial subitem (pZ 0.005), UPDRS part I (pZ 0.005), UPDRS
part II (p < 0.001), and SEADL (p Z 0.001). Sustained
improvementwas observed only in theUPDRS part III subitems
of tremor (7.41  4.4 vs. 6.58  5.2, pZ 0.358) and rigidity
(10.22  3.9 vs. 9.84  3.6, p Z 0.523), as well as part IV
(5.07  3.8 vs. 4.58  2.4, p Z 0.132), although these im-
provements were not statistically significant (Table 2, Fig. 2).
LEDD and stimulation parameters
When compared to the preoperative LEDD (766.15 51.0mg),
significant reductions were observed at both the 1-year
Table 1 UPDRS and SEADL in the off-medication/on-stimulation condition.
Target and condition Scores p





Mean (SD) Mean (SD) Mean (SD) 1-year
UPDRS III total 47.34 (14.0) 23.02 (9.0) 28.32 (10.0) 0.001* 0.001* 0.001**
Tremor 7.41 (4.4) 1.12 (1.6) 1.05 (1.5) 0.001* 0.001* 0.935
Rigidity 10.22 (3.9) 4.15 (2.9) 4.71 (3.2) 0.001* 0.001* 0.357
Bradykinesia 19.32 (5.8) 11.51 (4.2) 14.32 (4.6) 0.001* 0.001* 0.001**
Posture-Gait 3.98 (1.5) 2.34 (1.3) 3.16 (1.4) 0.001* 0.006* 0.001**
Axial 8.73 (3.1) 5.61 (2.6) 7.13 (3.1) 0.001* 0.008* 0.001**
UPDRS I 3.34 (1.9) 2.17 (1.4) 3.26 (1.9) 0.001* 0.276 0.001**
UPDRS II 19.59 (8.3) 9.61 (5.1) 14.37 (7.1) 0.001* 0.001* 0.001**
UPDRS IV 5.07 (3.8) 1.07 (1.5) 1.97 (2.2) 0.001* 0.001* 0.007**
UPDRS I, II, III, IV 72.98 (24.2) 35.88 (13.6) 47.92 (17.5) 0.001* 0.001* 0.001**
Hoehn &Yahr Stage 3.09 (0.8) 2.39 (0.5) 2.83 (0.7) 0.001* 0.002* 0.001**
SEADL % 77.07 (2.7) 94.76 (7.7) 79.74 (21.6) 0.001* 0.260 0.001**
Data are presented as mean (SD).
*Improvement, p < 0.016.
**Worsening, p < 0.016.
SD Z standard deviation; SEADL Z Schwab and England Activities of Daily Living; UPDRS Z Unified Parkinson’s Disease Rating Scale.
838 J.-L. Jiang et al.(398.59  51.6 mg; p < 0.001) and 5-year (533.26  51.0 mg;
p Z 0.050) follow-ups. However, a 55.5% increment was
observed between the 1-year and 5-year follow-ups. The
stimulation parameters did not show a significant difference
between the 1-year and the 5-year follow-ups (Table 3).Discussion
Significant improvements were observed in the UPDRS parts
I, II, III, and IV scores and SEADL scores in the off-
medication/on-stimulation condition at the 1-year follow-
up. Five years after STN-DBS, improvements in UPDRS
scores were observed only for parts II, III, and IV when
compared to the baseline off-medication condition. In the
off-medication/off-stimulation condition, no significant
improvement was observed. At the 5-year follow-up, sig-
nificant deteriorations were observed in the scores for the
UPDRS part III axial sub-item, UPDRS part I, UPDRS part II,
and SEADL when compared to the baseline.
Apart from symptoms assessed by the UPDRS part I
(mentation, behavior, and mood) and SEADL, short-term
and long-term significant symptom improvement as a result
of STN-DBS was observed in this 5-year cohort study.
These findings are in line with previous 5-year
studies,4,7,10,11 and a more recent study in patients with 8
years of follow-up12 reported prolonged improvement in
rigidity and tremor but progressive deterioration of axial
signs.
The nonmotor features of PD, including depression,
anxiety, cognitive decline, pain, fatigue, insomnia, and
autonomic dysfunction, have been identified as significant
factors in the diminished quality of life of PD patients.18,19
UPDRS part I scores returned to the baseline level at the 5-
year follow-up, as a result of a deterioration in ADL, despite
persistent significant improvements in motor function. The
data presented in this report could be evidence thatnonmotor symptoms are contributing factors to the quality
of life in PD patients.4
In our study, the effects of STN-DBS declined signifi-
cantly between the 1-year and 5-year follow-ups for all the
parts of the UPDRS, the H&Y stage, and the SEADL
(p < 0.001, p Z 0.001, and p < 0.001, respectively). An
elevation of the LEDD was also observed. Our results echo
previous studies reporting that the clinical benefits of STN-
DBS, particularly regarding axial symptoms, may decline
over the years.4,7,10,11,13 Moro et al20 proposed that STN-
DBS patients show a deterioration of the levodopa
response after 5e6 years, suggesting a closer relationship
to the progression of PD than to the target of stimulation,
the stimulation parameters, or the medication dose
reduction.
Tremor was presented as the best target symptom for
DBS. In this report, tremor had the greatest magnitude of
improvement at 1 year, and it remained steady after 5
years, even during the off-medication period. A post mor-
tem study showed that tremor-dominant PD patients pro-
gressed more slowly to H&Y stage 4 than patients with
akinetic-rigid symptoms.21 There is converging evidence
from post mortem and nuclear imaging studies suggesting
that patients with tremor-dominant PD have relatively
benign nigrostriatal degeneration.22 Another study also
suggested that neural activity during STN-DBS is an impor-
tant modulator of the neural networks that are responsible
for both resting and postural tremor genesis in PD.23
Moreover, STN-DBS was more effective than medication in
reducing the amplitude and increasing the frequency of
resting and postural tremor.23 This evidence may also
explain why the tremor features of PD take a more benign
course after STN-DBS.
Our study showed a substantial reduction in the daily
need for antiparkinsonian medications. These results are
comparable to those reported in another published study
with a long-term follow-up.23 Nevertheless, between 1 year
Figure 2 Time course evolution of the baseline scores for the Unified Parkinson’s Disease Rating Scale (parts I, II, III, and IV), the
Hoehn and Yahr stage and the Schwab and England Activities of Daily Living in the off-medication/on-stimulation and off-
medication/off-stimulation conditions from preoperation to 1 year and 5 years postoperation. The off-medication/on-
stimulation had lower Unified Parkinson’s Disease Rating Scale parts I, II, III, and IV scores and lower Hoehn and Yahr stages
than the off-medication/off-stimulation at the 5-year follow-up.
Effects of STN-DBS in Parkinson’s disease 839and 5 years postoperation, the LEDD significantly increased
by 55.5% but remained much lower than prior to the sur-
gery. The postoperative degradation of the L-dopa response
could be related to the progression of the disease,4,7 a
reduction in the dopaminergic receptor sensitivity due to a
reduction in anti-PD drug doses, or a more direct effect of
STN-DBS.20 Previous studies also confirmed that the L-dopa
response is reduced after STN-DBS and that the long-term
symptom improvement from STN-DBS is not predicted by
the preoperative dopaminergic response.10
This study has several limitations, including the lack of a
control group and double-blinded assessments. Only 41% of
the patients who received implants for bilateral stimulation
of the subthalamic nucleus at our institute from 2002 to
2007 participated in this 5-year cohort study, confirming
the difficulty of conducting long-term follow-up studies in
PD patients.10,12 Blinded assessments were difficult to
perform because most of the patients were able to guesswhether the DBS was turned on, which was especially true
in the patients who might experience transient paresthesia
during the manipulation. Additionally, placebo effects in
Parkinson’s disease are rarely sustained in repeated
testing.24 Finally, the development of nonmotor and atyp-
ical parkinsonian features may be a major limiting factor in
any therapy for PD if the focus is limited to the conse-
quences on the nigrostriatal dopaminergic efficiency.25
Nevertheless, our study’s evaluation period was 5 years,
and repeated assessments were performed by the same
investigators. The reliability of using scales is good, espe-
cially considering the magnitude of the changes that were
observed in the motor scores over time.
In conclusion, the long-term effects of STN-DBS on motor
function are promising, although the magnitude of their
effectiveness declined in the temporal domain. In terms of
the UPDRS, nonmotor symptoms had the least effectiveness
during long-term follow-up and were closely related to a
Table 2 UPDRS and SEADL in the off-medication/off-stimulation condition.
Target and condition Scores p





1-yearMean (SD) Mean (SD) Mean (SD)
UPDRS III total 47.34 (14.0) 44.98 (13.5) 50.39 (13.7) 0.343 0.137 0.003**
Tremor 7.41 (4.4) 7.02 (4.6) 6.58 (5.2) 0.728 0.358 0.525
Rigidity 10.22 (3.9) 9.02 (3.4) 9.84 (3.6) 0.043 0.523 0.032
Bradykinesia 19.32 (5.8) 18.66 (5.4) 21.34 (5.7) 0.548 0.045 0.001**
Posture-Gait 3.98 (1.5) 3.88 (1.8) 4.53 (1.5) 0.578 0.052 0.031
Axial 8.73 (3.1) 8.68 (3.8) 10.66 (4.2) 0.682 0.005** 0.001**
UPDRS I 3.34 (1.9) 3.34 (1.6) 4.89 (2.0) 0.246 0.005** 0.001**
UPDRS II 19.59 (8.3) 19.59 (9.6) 26.84 (9.8) 0.839 0.001** 0.001**
UPDRS IV 5.07 (3.8) 5.07 (3.4) 4.58 (2.4) 0.426 0.132 0.359
UPDRS I, II, III, IV 72.98 (24.2) 72.98 (24.4) 86.71 (25.0) 0.418 0.008** 0.001**
Hoehn & Yahr Stage 3.09 (0.8) 3.09 (0.8) 3.67 (0.9) 0.139 0.039 0.002**
SEADL % 77.07 (2.7) 77.07 (20.5) 52.37 (28.5) 0.739 0.001** 0.001**
Data are presented as mean (SD).
*Improvement, p < 0.016.
**Worsening, p < 0.016.
SD Z standard deviation; SEADL Z Schwab and England Activities of Daily Living; UPDRS Z Unified Parkinson’s Disease Rating Scale.
Table 3 Stimulation parameters between 1 year and 5 years after surgery.
1 year 5 years
Ch1 Ch2 Ch1 Ch2
Voltage 3.23  0.58 3.12  0.75 3.54  0.44 3.57  0.42
Pulse width 62.18  7.86 61.13  5.77 63.1  9.3 64  10.37
Frequency 139.36  16.64 138.96  16.36 130.69  23.13 131.17  22.88
Data are presented as mean  SD.
Ch Z channel.
840 J.-L. Jiang et al.decline in the ADL of the PD patients. Disease progression
seems to be inevitable despite STN-DBS.
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